Barinthus Biotherapeutics (STU:2AB) Growth Rank: 0 (As of Jul. 05, 2026)


STU:2AB Barinthus Biotherapeutics PLC STU:2AB
14 GF Score
Price €0.52
GF Value €0.94
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics Growth Rank?

Barinthus Biotherapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Barinthus Biotherapeutics Growth Rank Related Terms

STU:2AB
14GF Score
Barinthus Biotherapeutics PLC STU:2AB
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of €0.52 is trading 44.7% below its estimated GF Value™ of €0.94.

Key valuation signals for STU:2AB:

  • Growth Rank: 0
  • GF Value™: €0.94 vs. price of €0.52 (44.7% below fair value)
  • GF Score™: 14/100 with 1 warning sign

No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Other Exchanges BRNS:USA
Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score

Get the complete analysis for STU:2AB

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.52
Price
€0.94
GF Value